Disclosures for "Transition from Intravenous Immunoglobulin to Efgartigimod PH20 SC in Participants with Chronic Inflammatory Demyelinating Polyneuropathy: A Phase 4 Study in Progress"
-
The institution of Dr. Hussain has received research support from Alnylam Pharma.
-
Dr. Guptill has received personal compensation for serving as an employee of argenx. Dr. Guptill has stock in argenx.
-
Author has nothing to disclose
-
Ms. Remmerie has received personal compensation for serving as an employee of argenx. Ms. Remmerie has stock in argenx.
-
Erik Hofman has received personal compensation for serving as an employee of argenx BV. Erik Hofman has stock in argenx BV.
-
Mr. De Roeck has received personal compensation for serving as an employee of argenx. Mr. De Roeck has stock in argenx.
-
Author has nothing to disclose
-
Dr. Anokhina has received personal compensation for serving as an employee of argenx.
-
Dr. Van Hoorick has received personal compensation for serving as an employee of argenx. Dr. Van Hoorick has stock in argenx.